SanofiMEX:SAN1N 72 Days Payable is 186.48 as of Dec. 2025, which is 5% above its 10-year median of 178.28. GuruFocus rates MEX:SAN1N with a GF Score™ of 72/100 and a GF Value™ of MXN2,117.09 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 921 Drug Manufacturers companies, Sanofi ranks better than 85.12% on this metric.
Sanofi's average Accounts Payable for the
six
months ended in Dec. 2025 was MXN154,426 Mil. Sanofi's Cost of Goods Sold for the
six
months ended in Dec. 2025 was MXN151,130 Mil.
Hence, Sanofi's Days Payable for the
six
months ended in Dec. 2025 was 186.48.
The historical rank and industry rank for Sanofi's Days Payable or its related term are showing as below:
MEX:SAN1N'
s Days Payable Range Over the Past 10 Years
Min: 138.38 Med: 178.28 Max: 208.56
Current: 205
During the past 13 years, Sanofi's highest Days Payable was 208.56. The lowest was 138.38. And the median was 178.28.
MEX:SAN1N's Days Payable is ranked better than 85.12% of 921
companies
in the Drug Manufacturers industry
Industry Median: 90.69
vs MEX:SAN1N: 205.00
Sanofi's Days Payable
increased
from Dec. 2024 (179.79) to Dec. 2025 (186.48).
It may suggest that Sanofidelayed paying its suppliers.
Sanofi Days Payable Related Terms
Sanofi Days Payable Historical Data
* Premium members only.
The historical data trend for Sanofi's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:SAN1N vs LLY, JNJ, ABBV: Days Payable Comparison
For the Drug Manufacturers - General subindustry, Sanofi's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sanofi Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sanofi's Days Payable distribution charts can be found below:
* The bar in red indicates where Sanofi's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Sanofi's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sanofi (MEX:SAN1N) has a Days Payable of 186.48 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Sanofi and its competitors. This is near median its historical median of 178.28. Over the past decade, Sanofi's Days Payable has ranged from 138.38 to 208.56. According to the industry distribution chart, Sanofi ranks #137 out of 921 companies in the Drug Manufacturers industry, placing it in the top 14.9%.
Is Sanofi's Days Payable too high?
Sanofi's current Days Payable of 186.48 is near median its 10-year median of 178.28. Over the past 10 years, this metric has ranged from a low of 138.38 to a high of 208.56. The Drug Manufacturers industry median Days Payable is 90.69. Sanofi's value of 186.48 is 105.6% above this industry median. Based on the distribution chart, Sanofi ranks #137 out of 921 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Sanofi has a GF Score™ of 72/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sanofi's Days Payable compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Sanofi ranks #137 out of 921 companies for Days Payable. This places Sanofi in the top 15% of its industry — outperforming the majority of peers. The industry median Days Payable is 90.69. Sanofi's value of 186.48 is 105.6% above this benchmark. Historically, Sanofi's own Days Payable has ranged from 138.38 to 208.56 over the past decade. While the company's 10-year median is 178.28 vs. the industry median of 90.69, Sanofi has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.69, based on 921 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sanofi's current Days Payable of 186.48 is 105.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Sanofi and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sanofi's current Days Payable is 186.48, which is near median its own 10-year median of 178.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sanofi stock overvalued right now?
Based on GuruFocus' analysis, Sanofi (MEX:SAN1N) is currently considered Possible Value Trap. The stock's GF Value™ is MXN2,117.09, compared to a current price of MXN1,486.08 — trading 29.8% below its estimated fair value. The current Days Payable is 186.48, which is near median its 10-year median of 178.28 and 105.6% above the Drug Manufacturers industry median of 90.69. Sanofi's overall GF Score™ is 72/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Sanofi (MEX:SAN1N), the current Days Payable is 186.48 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sanofi (MEX:SAN1N) Overvalued in 2026?
Based on GuruFocus' analysis, Sanofi stock appears to be undervalued.
The current stock price of MXN1,486.08 is trading 29.8% below its estimated GF Value™ of MXN2,117.09.
GuruFocus considers Sanofi to be Possible Value Trap.
Key valuation signals for MEX:SAN1N:
Days Payable: 186.48 (near median its 10-year median of 178.28)
GF Value™: MXN2,117.09 vs. price of MXN1,486.08 (29.8% below fair value)
Industry Position: 105.6% above the Drug Manufacturers median (#137 of 921)
No single metric tells the full story. See the MEX:SAN1N stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
72GF Score
Get the complete analysis for MEX:SAN1N
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:SAN1N has been successfully added to your 
